• PAD4-IN-2 TFA: Precision Inhibition of Tumor NET Formation

  2026-07-10

  PAD4-IN-2 TFA (Compound 5i TFA) enables highly selective inhibition of histone H3 citrullination and NET formation in tumor models, offering a powerful tool for dissecting tumor immune microenvironment dynamics. Its meta-phenylboronic acid modification ensures targeted uptake and minimal toxicity, setting a new benchmark for translational cancer research.

• Celastrol Disrupts CAV-1/SCP2 Axis to Induce Mitophagy in Li

  2026-07-09

  This study reveals that celastrol suppresses liver cancer by inducing mitochondrial cholesterol overload and mitophagy through inhibition of the CAV-1/SCP2 axis. The findings highlight a novel organelle-specific metabolic vulnerability and inform strategies for targeting cholesterol metabolism in hepatocellular carcinoma models.

• Standardized Whole-Blood Immunometabolism Assays: Protocol A

  2026-07-09

  This protocol study pioneers a standardized method for analyzing immune responses in fresh human whole blood under controlled metabolic modulation. By directly linking metabolic pathway inhibition to cytokine output, it provides a robust foundation for reproducible immunometabolism research and facilitates exploration of targeted immune interventions.

• Birinapant (TL32711): Applied Workflows for Apoptosis Induct

  2026-07-08

  Birinapant (TL32711) enables precise modulation of apoptosis in cancer research, supporting advanced assay designs and translational models targeting IAP pathways. Learn how to implement, troubleshoot, and optimize this SMAC mimetic for reproducible results in apoptosis induction and chemoradiotherapy resistance studies.

• Evaluating ATR Inhibitor Radiosensitization in 2D and 3D Mod

  2026-07-08

  This study provides a systematic comparison of molecular targeted radiosensitizers, including ATR inhibitors, in both 2D and 3D lung cancer cell models. The findings highlight how physiologically relevant 3D culture systems can reveal additional context-dependent radiosensitization effects, guiding preclinical prioritization of candidate DNA damage response inhibitors.

• CB-839 (Telaglenastat): Optimizing Cancer Metabolism Researc

  2026-07-07

  CB-839 (Telaglenastat) empowers researchers to dissect cancer cell metabolism with precision, targeting glutaminase 1 for robust preclinical insights. This guide highlights advanced experimental workflows, troubleshooting strategies, and actionable protocol enhancements for maximizing the impact of CB-839 in both mechanistic and translational cancer studies.

• 4-tert-Butylphenol Induces Ferroptosis in Carp Liver: Mechan

  2026-07-07

  This study demonstrates that the environmental pollutant 4-tert-butylphenol (4-tBP) induces ferroptosis in common carp hepatocytes via oxidative stress, iron overload, and dysregulation of the SLC7A11/GSH/GPX4 and ATF4/HSPA5/GPX4 axes. Critically, the work shows that pretreatment with Ferrostatin-1 (Fer-1) can ameliorate 4-tBP-induced hepatocyte injury, revealing both mechanistic insight and potential intervention strategies for aquatic toxicology.

• Astrocytic GAT-3 Modulates Synaptic Transmission in Dentate

  2026-07-06

  The referenced study uncovers how astrocytic GAT-3 regulates synaptic transmission and memory formation in the dentate gyrus by modulating astrocytic calcium signaling and presynaptic receptor activity. These findings reveal a previously underappreciated role for astrocytes in hippocampal circuit modulation, with potential implications for cognitive disorder research.

• Decoding Nicotine Biosynthesis: Five-Component Metabolon Rev

  2026-07-06

  Chang et al. (2026) resolve the complete enzymatic steps of nicotine biosynthesis in tobacco, detailing the assembly and function of a five-component vacuolar metabolon that coordinates synthesis and transport. These findings provide a molecular blueprint for engineering nicotine production and investigating plant alkaloid biosynthetic pathways.

• SU5416 (Semaxanib): Precision Angiogenesis Inhibition in Res

  2026-07-05

  SU5416 (Semaxanib) offers unique dual-action as a VEGFR2 inhibitor and AHR agonist, enabling targeted suppression of angiogenesis and immune modulation in cancer and vascular models. This article translates the latest experimental breakthroughs and troubleshooting wisdom into actionable workflows, ensuring maximum reproducibility across advanced research domains.

• Magnetic Bispecific Nano-antibodies Enable In Vivo CAR-T-Mim

  2026-07-04

  This study introduces a magnetic bispecific nano-antibody system (M-BiNanoAb) that enables direct in vivo programming and magnetic guidance of CAR-T-mimicking cells to solid tumors. The approach addresses longstanding barriers in solid tumor immunotherapy, offering enhanced T cell infiltration and cytotoxicity without the complexities of ex vivo CAR-T cell manufacturing.

• Phosphatase Inhibitor Cocktail 1: Precision in Phosphoproteo

  2026-07-03

  Phosphatase Inhibitor Cocktail 1 (100X in DMSO) from APExBIO is engineered for robust preservation of protein phosphorylation states, enabling high-fidelity phosphoproteomic analysis even in complex biological samples. This guide delivers actionable workflows, advanced troubleshooting, and practical insights for researchers seeking uncompromised data quality in signaling pathway studies.

• Ruthenium Red: Unveiling Calcium Dynamics in Mechanotransduc

  2026-07-03

  This thought-leadership article explores how Ruthenium Red, as a benchmark Ca2+ transport inhibitor, empowers translational researchers to dissect the interplay between cytoskeleton-dependent mechanotransduction, calcium signaling, and autophagy. Drawing on recent mechanistic breakthroughs and validated protocols, the discussion offers actionable guidance for optimizing experimental workflows and highlights APExBIO's Ruthenium Red (B6740) for reproducibility and specificity.

• Rottlerin PKC Inhibitor: Applied Workflows and Troubleshooti

  2026-07-02

  Rottlerin stands out as a selective PKC inhibitor, empowering detailed mechanistic research in apoptosis, cell proliferation, and pathogen-host interactions. This article bridges reference breakthroughs with actionable protocols, troubleshooting advice, and comparative insights to accelerate robust experimental outcomes.

• LMO2-LDB1 Complex Drives AML Progression: Mechanistic Insigh

  2026-07-02

  This article examines how the LMO2-LDB1 transcriptional complex promotes acute myeloid leukemia (AML) by supporting leukemic cell proliferation and survival. The reference study clarifies the molecular relationship between LMO2 and LDB1 in AML, suggesting new avenues for targeted intervention.

455 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page